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Abstract (197 words) 
Clinicians diagnose thyroid dysfunction based on TSH and FT4 testing. However, the 
current lack of comparability between assays limits the optimal use of laboratory 
data. The International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) gave a mandate to the Committee for Standardization of Thyroid Function 
Tests (C-STFT) to resolve this limitation by standardization. Recently, the Committee 
members and their partners felt ready to set the step towards the technical 
recalibration. However, before implementation, they were furthered by the Food and 
Drugs Administration (FDA) to develop a tool to assess the sustainability of the new 
calibration basis. C-STFT began to use 2 online applications, i.e., the “Percentiler” 
and “Flagger”, with the intention to assess their utility for this purpose. The tools 
monitor the course of instrument-specific moving medians of outpatient results 
(Percentiler) and flagging rates (Flagger) from data of individual laboratories grouped 
by instrument/assay peer. They additionally document the mid- to long-term medians, 
hence, are quality indicators of stability of performance of both laboratories and 
peers/assays. Here, the first experiences built up in the pre-standardization phase 
are reported. They suggest the suitability of both applications to document the 
sustainability of the calibration basis in the post-standardization phase.
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Introduction 
Given the prevalence and severity of different forms of thyroid disease, the yearly 
number of tests performed worldwide is huge [1-4]. Clinicians mainly rely on the 
analysis of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) for the 
diagnosis of thyroid dysfunction and patient follow-up. The frequency of thyroid 
function testing translates in an enormous impact of the disease on the healthcare 
system. In this regard, it is generally recognized that, to reduce the expenses for 
healthcare from laboratory analysis, comparability of measurement data over time, 
location and across assays would be utmost beneficial. Indeed, once this is achieved, 
laboratory data can meet modern clinical and public health needs, such as the 
definition and use of common reference intervals/clinical decision limits, development 
of evidence-based clinical practice guidelines for application of consistent standards 
of medical care, translation of research into patient care and disease prevention 
activities, inclusion of laboratory data in electronic patient records, etc. [5]. However, 
to accomplish this, in depth transformation of the current laboratory landscape in 
general but for thyroid function testing in particular is required. Indeed, the problem of 
observed between-assay discrepancies needs to be resolved [6,7].  
The International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) decided to pay attention to these needs. In 2005, the Scientific Division 
formed the Working Group for Standardization of Thyroid Function Tests (WG-STFT) 
with the mission statement to document the standardization status and intrinsic 
quality of current thyroid hormone immunoassays. The focus of the activities should 
be on TSH and FT4 testing, and where necessary, on improving the standardization 
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status [6,7]. In 2012, the WG was transformed into a Committee (C-STFT) to broaden 
the scope of stakeholders [8].  
The achievements of the WG up to now are described elsewhere [6,7,9-16]. 
They comprise developing reference measurement systems for standardization of 
FT4 and harmonization of TSH, demonstrating the feasibility of their use as a uniform 
calibration basis for commercial in-vitro diagnostic (IVD) thyroid function tests, and 
designing a step-up approach based on several dedicated method comparison 
studies to allow new manufacturers to join the standardization activities. Recently the 
C-STFT set the step to the technical recalibration process of FT4 and TSH assays by 
a method comparison with clinically relevant panels of samples (results currently 
under investigation). Although in theory this process completes the establishment of 
a uniform calibration basis of the assays – at least for diagnosis and follow-up of 
uncomplicated hypo- and hyperthyroidism – immediate implementation is not 
possible but needs careful preparation. One of the actions currently undertaken in 
this regard was that the Committee – comprising laboratory professionals and IVD 
manufacturers – visited the Food and Drug Administration (FDA) authorities. They 
presented the technical approach, discussed its acceptability and the plans before 
implementation. The Committee got a positive response from the FDA, who 
particularly welcomed the plan to establish a dialogue basis with an as broad 
spectrum of stakeholders as possible, and investigate with them the benefits but also 
the risks associated with implementing the standardized/harmonized IVD assays. 
The benefit-risk analysis recently has been initiated, among others, at the level of 
medical laboratories (internally by consultation of delegates designated by the IFCC 
Member Societies) and clinicians/patients [e.g., 17]. In addition, the FDA furthered 
the Committee to document – preferably at the level of real patient results – the 
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sustainability of the post-standardization calibration status of the participating IVD 
assays. The Committee got by courtesy of STT-Consulting and the Chair (currently 
Thienpont & Stöckl Wissenschaftliches Consulting) access to 2 new quality 
management tools to assess whether they could serve the above purpose implied by 
the FDA. Note that as described elsewhere the tools are part of the overarching 
“Empower project” [18-21]. One tool, called the “Percentiler” monitors daily outpatient 
medians to reflect the stability/variation of performance at the level of the individual 
laboratory and its peer group. Its potential to build a global evidence base on IVD test 
stability across laboratories and peers/manufacturers has been shown before from 
application for clinical chemistry analytes. The second tool, the “Flagger”, monitors 
flagging of results against reference intervals or decision limits used in the individual 
laboratory, but also at the peer group level. It is complementary to the “Percentiler” in 
that it directly translates the effect of analytical quality/(in)stability on flagging as 
surrogate medical decision making [22]. In view of this potential the C-STFT decided 
to start using the Percentiler and Flagger (in cooperation with the Empower team) in 
the framework of its standardization activities. One important matter of concern that 
needed investigation was whether the tools would similarly be useful to monitor the 
stability of FT4 and TSH assays as they are for clinical chemistry ones, particularly, 
because it could be anticipated that the reported median and flagging rate values 
would be based on a substantially lower number of results per day. The Empower 
team invited laboratories, already using the applications for clinical chemistry 
analytes, to extend their participation to FT4 and TSH. For obvious reasons, the 
focus was on laboratories using the IVD test systems/assays involved in the C-STFT 
standardization/harmonization project. The C-STFT’s intention was to explore the 
utility of both tools in the pre-standardization phase, and if positive, to fully exploit 
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them in the post-standardization phase for the purpose implied by the FDA. Here, we 
report on behalf of C-STFT on the experience built up in the pilot study. 
 
Material and methods 
The way the data are collected in both applications has been described in detail 
elsewhere [19-21]. Participation is free of charge. In brief, laboratories calculate – 
preferably by an automatic function in their Laboratory Information System (LIS) or, if 
not available, manually – instrument-specific daily medians (preferably) from 
outpatient results. The data are automatically sent by e-mail on a daily basis or batch 
wise to the Percentiler’s and Flagger’s MySQL database. For the Flagger application 
laboratories also report the daily flagging rate in percentage of the total number of 
generated results. Whereas the Empower team can investigate the complete 
database at the individual laboratory and peer group level, the participating 
laboratory only has access to its own data via a user interface (to access via a 
specific login and password at https://thepercentiler.be and https://theflagger.be, 
respectively). These interfaces have several functionalities, such as downloadable 
charts of the laboratory’s instrument-specific moving medians of patient results 
(Percentiler) and flagging rates (Flagger) in time, as well as a table with summary 
statistics (bias, robust CV). The moving median charts also show the mid- to long-
term medians of the laboratory and its peer group. In the Percentiler application the 
respective numerical values are documented in the statistics table, where also a 
target median is given (see below). The laboratory bias is compared to the peer 
group and target median. The deviation (in %) from the target is evaluated against 
desirable bias limits from biological variation, i.e., 3.3% for serum FT4 and 7.8% for 
serum TSH, respectively [23]. These limits are visualized in the charts by a gray zone 
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around the laboratory’s mid- to long-term median to reflect the stability of 
performance. Violations of the limits that last more than 1 week are considered 
significant. With regard to the aforementioned target median used to assess the bias 
of the individual laboratory and peer group medians, currently the all-laboratories’ 
median is utilized. In the pre-standardization phase the overall median for FT4 is 15 
pmol/L with ± 0.5 pmol/L as limits, for TSH 1.56 mIU/L ± 0.12 mIU/L, respectively. In 
the Flagger application a certain relative percentage around the long-term median 
(with an absolute minimum of 1%) is used as the limit, which should not be violated. 
For FT4 and TSH the limit is preliminary set to 30% [22]. 
 
Results 
In the Percentiler application, currently (March 2016) 76 laboratories participate with 
158 instruments, while in the Flagger, 33 laboratories supply data from 44 
instruments. The number of laboratories and test systems per manufacturer are listed 
in Table 1, including the average participation time per peer group. This should give 
an indication of the number of data points accounted for in this pilot study (1 data 
point (1 median value) per assay per instrument per day is received). For this study, 
we distinguished in the Percentiler between 5 peer groups, i.e., Roche Cobas, 
Siemens Centaur, Abbott Architect, Beckman Synchron, and OCD Vitros, whereas in 
the Flagger, only the Roche Cobas peer group is currently sufficiently substantiated. 
Therefore, the data given for this application are very preliminary.  
We calculated from the patient data in the Percentiler the respective peer 
group medians for both FT4 and TSH. For FT4 the peer group medians ranged in the 
pre-standardization/harmonization phase from ~11.7 to 16 pmol/L, for TSH from ~1.2 
to 1.7 mIU/L, respectively. In Figure 1, the match of the peer group medians in this 
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pilot study with those from the previous Phase I method comparison studies is shown 
[6,7]. 
Although the time period of participation is still short for the majority of assays 
(on average 11 months), most laboratories generally showed a stable performance 
for both analytes. However, in some individual cases we observed greater variation in 
performance (drifting or shifting medians), occurrence of a transient bias, between-
instrument differences within a laboratory, etc. A few representative examples are 
given: in Figure 2A a laboratory is documented with an acceptable analytical stability 
for TSH analysis on all instruments; indeed all moving medians are nicely between 
the stability limits and concordant with the peer group median; in contrast, Figure 2B 
shows a laboratory with highly variable FT4 moving medians for all instruments it 
uses; in Figure 2C the concerned laboratory has clear shifts in its FT4 performance 
(note the moving medians exceeding the stability limits), while the laboratory shown 
in Figure 2D performs for TSH with a substantial difference between the 2 
instruments it uses. 
Figure 3 shows a peculiar observation made in 1 of the peer groups, i.e., 2 
subgroups of laboratories having their long-term median at different levels.  
When comparing the %-hypo and %-hyper value in the Flagger with the 
variation of the moving medians of the corresponding laboratories in the Percentiler, 
the interplaying effect of both tools is visible, i.e., an increase of the median values 
results in a decrease of the %-hypo and increase of the %-hyper, respectively and 
vice versa. This is documented in Figure 4, where indeed the upward (until 
September 2014) and downward trends in the FT4 median values in the Percentiler 
graph are mirrored in the corresponding %-hypo (5B) and %-hyper (5C) medians of 
the Flagger. 
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Discussion 
This pilot study was intended to apply the Percentiler and Flagger – initially 
developed for clinical chemistry analytes – also for FT4 and TSH. We were 
particularly interested to learn whether the tools can serve the purpose of 
monitoring/demonstrating the stability of the assays’ calibration status. This kind of 
tools were indeed furthered from the C-STFT by the FDA as part of a benefit-risk 
analysis before implementing the recalibrated assays. As previously described, the 
big advantage of both Percentiler and Flagger is that they work with results from 
patient samples. This prevents questioning of the observations because of non-
commutability issues typically associated with processed materials used in external 
quality control surveys conducted for the same purpose [24]. That said, there may 
well be merit in looking at this data in conjunction with data from a mature, frequent 
distribution, data-rich external quality assurance services program which uses 
material at the more commutable end of the spectrum and which already regularly 
produces method trend data [e.g., 25]. It also circumvents discussions whether 
internal quality control data are sufficiently suited to reflect variation in 
laboratory/instrument/assay performance due to, for example, reagent and calibrator 
lot changes [26]. Although we conducted this study in the pre-standardization phase 
in which all FT4 and TSH assays still work with their original calibration basis, our 
reasoning was that, if positive, the tools would likewise be useful in the post-
standardization phase. On long-term we aim at having all 
manufacturers/instruments/assays involved in the C-STFT activities represented in 
the Percentiler and Flagger application by a sufficient number of laboratories (we aim 
at an input of data from minimum 20 instruments per manufacturer for solid peer 
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group observations). In this pilot phase we could only distinguish 6 peer groups, of 
which 5 still are absolutely preliminary, which requires cautious interpretation (data 
input from too few instruments). Nevertheless, we believe that also observations from 
an exploratory phase are helpful to build experience. We are confident that the IVD 
partners of C-STFT will be eager enough to bring more customers on board. After all, 
meeting the FDA demands might facilitate the revision of the 510k clearance of their 
recalibrated assays.  
 We first explored the utility of the Percentiler to do quasi real-time monitoring 
of FT4 and TSH outpatient medians in the individual laboratory. This monitoring is a 
quality indicator of stability of performance of both the laboratory and assay. We used 
the experience from applying the tool in clinical chemistry for comparison [18-20]. As 
previously explained, the on-line user interface shows the participating laboratory for 
each instrument the course of the moving median, the mid- to long-term median as 
well as that from the peer group. Interpretation of the graphs in terms of acceptable 
performance is facilitated by including a stability zone around the long-term median. 
The limits of that zone are desirable bias limits inferred from the biological variation 
model [23]. Our short time experience with the thyroid hormone assays learns that in 
most laboratories the stability of performance was quite satisfactory (see Figure 2A). 
Indeed, no significant or only borderline violation of the FT4 and TSH limits was 
observed in 80% of the laboratories participating for minimum 6 months; for TSH this 
was the case for >95% of the participants. Nevertheless, we want to emphasize that 
the variability of the moving median for FT4 and TSH was higher than in comparison 
to that for clinical chemistry analytes. As explained before, this was anticipated from 
the fact that the respective daily medians are calculated from fewer results than is the 
case for the common clinical chemistry analytes, simply because thyroid hormone 
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measurements are requested less frequently. However, the increased variability due 
to fewer results can partially be solved by calculating the moving median from a 
higher number of daily medians (the options are n = 5, 8 and 16). In other cases this 
is not effective, most probably pointing to a real increase in analytical variability (e.g., 
Figure 2B). Hence, we suggest that the application of the Percentiler in the post-
standardization phase might better serve the purpose, if we could focus on 
laboratories with a high throughput. In approximately 20%, 8% and 3% of the 
laboratories participating during  half a year, we observed respectively 1, 2 or 3 
significant event(s) violating the FT4 stability limits (note the events observed for TSH 
in 5% of the laboratories were borderline). Upon investigation by the concerned 
laboratories, this was either due to lot changes, recalibration, but mostly reagent 
instability; also differences between instruments were observed (see Figure 2C and 
2D). Nevertheless, we want to repeat that the observations still must be interpreted 
with caution [19,20]. Consultation with the concerned laboratory is necessary to be 
sure that, for example, the observed discrepancy between instruments is not due to 
the fact that they are used for preferential measurement of certain patient samples. 
Indeed, from contacting participants in the Percentiler application for clinical 
chemistry analytes, we learnt that laboratories sometimes concentrate the samples 
from, for example, policlinic patients presenting themselves in the morning for 
measurement on 1 instrument, while they reserve other instruments for measurement 
of, for example, day clinic patients (sometimes also identified as outpatient by the 
LIS).  
Some may argue that the violations are due to the fact that we use desirable 
bias limits inferred from biological variation, which are particularly narrow for FT4. 
However, as discussed above the violation rate was never of an extent that the 
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validity of the limits needed to be questioned. In the Percentiler, a laboratory’s FT4 
and TSH median values are compared with those of the peer group to which it 
belongs. This allows the laboratory to infer whether a shift or drift is due to its own 
performance (event only seen for the concerned laboratory), or rather to an 
assay/manufacturer event (e.g., a reagent or calibrator lot change applying for 
several laboratories of the peer group). However, to compare the participant with its 
peer, there are 2 prerequisites. First the peer group median should be sufficiently 
solid, which depends on the number of instruments used to calculate it (we aim at a 
minimum of 20). As mentioned before, our pilot study faced in this regard a problem, 
which prevents us to discuss here the performance of individual laboratories in 
comparison to their peer in greater detail. Nevertheless, we refer to the example in 
Figure 2A showing a laboratory performing in concordance with the peer group for 
nearly 1 year. The second prerequisite is that the medians should be calculated from 
outpatient results as discussed before [19,20]. Also the sample type analyzed in the 
participating laboratories may impact the medians. Currently we do not distinguish 
between medians from serum and plasma sample analysis, because only few 
participants measure plasma. However, if in the future that number would increase, it 
might be necessary to make sample-specific subgroups, to prevent that the 
differences in medians are interpreted as a calibration bias. The prerequisite of 
medians from outpatient results might apply even more for FT4 and TSH than for 
clinical chemistry analytes, because disease- or patient population-related 
concentrations might be quite influential. This is nicely illustrated from the above 
reported observation of 2 subgroups for TSH within the same peer group (Figure 3). 
In our opinion there were 2 explanations possible: either it was due to a real 
instrument bias in the subgroups, or to the way outpatients are defined in the 
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subgroup laboratories. To discriminate between these bias sources, we let analyze a 
same set of 20 samples in a laboratory from either subgroup. No significant bias 
between those 2 laboratories was found, from which we concluded that the observed 
difference was most likely due to a different patient population served by the 2 
subgroups, i.e., 1 group of laboratories measures TSH mostly for screening 
purposes, while the other does the measurements rather for follow-up of therapy. 
Some probably will see this as a limitation of the utility of the Percentiler to assess 
the bias of peer groups in the post-standardization phase. For many laboratories it is 
currently still difficult to unequivocally define results from outpatients due to 
limitations of their LIS. However, we are confident that it will be possible to resolve 
this weakness in the future, as we found already several LIS providers willing to 
adequately adapt their data transfer logic. Market forces most probably will make the 
others to follow.  
 In second instance, we explored the utility of the Percentiler to reflect the 
calibration status of IVD test systems/assays with particular emphasis on the 
sustainability thereof and/or the comparability between manufacturers. As further 
illustrated in Figure 1, it was comforting to observe how remarkably the medians of 
the 6 peer groups considered in this pilot study matched those seen in our Phase I 
studies [6,7]. The medians of these previous studies were perfectly suited for 
comparison, because they were calculated from results of method comparison 
studies with samples from apparently healthy (euthyroid) volunteers. Note that here 
we again report anonymously on the peer group data – as we did in all previous 
reports [6,7,14,16] – simply because the current study was only exploratory and did 
not yet include all manufacturers/instruments test systems. Anyhow, we see the 
observations in Figure 2 as a first basis of evidence for the utility of the Percentiler to 
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serve the purpose implied by the FDA. We expect this evidence to increase, the more 
solid the peer groups become (lower variability of the medians) [19,20]. Once we will 
have a sufficient number of participants for the different peer groups, we will be able 
to monitor their stability. Significant events observed for 1 or several of the 
instruments/assays will be used as an indication that the 
standardization/harmonization status might be jeopardized. Alternatively, it might 
point to a too high lot-to-lot variability. Therefore, these observations should form the 
basis for in-depth discussions on the lot to lot variability with the concerned 
manufacturers or be an incentive to conduct a new method comparison study to 
realign the shifted calibration basis. For this purpose, the C-STFT already prepared a 
follow up panel for TSH and works on an additional follow up panel for FT4. 
In the statistical table in the user interface, the individual laboratory- and peer 
group bias are assessed against the all-laboratories median targets for FT4 and TSH. 
This is a logical target in the pre-standardization phase, however, in the post-
standardization phase it will be adapted to the FT4 targets assigned by the 
conventional reference measurement procedure and the TSH all-procedure trimmed 
mean inferred from the method comparison on the harmonization panel.  
 Although our experience with the Flagger is still preliminary (only few 
laboratories send data on the flagging rate), we presume that the tool will be useful to 
investigate the impact of analytical quality/instability on daily surrogate medical 
decision making in the post-standardization phase, exactly as it does for clinical 
chemistry analytes [21]. This is, for example, already now nicely demonstrated for the 
case shown in Figure 4, where the fluctuations in the patient median values are 
mirrored in the flagging rate medians. The Flagger application is not strictly needed to 
assess the sustainability of the standardization status, but, we want to offer the 
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Percentiler-Flagger link as an interesting option to the participating laboratories. It 
indeed allows a laboratory to react rapidly on observed changes in the flagging rate, 
even if the underlying analytical instability is not yet considered significant [21]. 
Laboratories appreciate that they can prevent complaints from clinicians about an 
abnormal increase of the number of flagged results. But even if there are complaints, 
the Flagger might serve the laboratory to document that the perception of the 
clinician is not correct. We currently use a stability limit of 30% around the long-term 
median in the Flagger, but fine-tuning will be done after a longer follow-up.  
 
Conclusion 
By starting to use the Percentiler and Flagger application in the framework of the C-
STFT activities, their utility for monitoring the calibration basis of FT4 and TSH 
assays in the pre-standardization status is shown. This looks promising for their utility 
in the post-standardization phase to monitor the sustainability of the recalibration 
status achieved through the C-STFT project. Nonetheless, the here described 
limitations need to be resolved, mainly by expansion of the number of participating 
laboratories preferably with a high throughput, representation of all manufacturers on 
the project, and better definition of outpatient results.  
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Table 1: Overview of the number of instruments and the average participation time (in months) per peer group/manufacturer in the 1 
Percentiler and the Flagger. 2 
 The Percentiler The Flagger 
  
 Participants Instruments 
Average 
participation 
time (months) 
Participants Instruments 
Average 
participation 
time (months) 
  
Total 76 158 11 33 44 6 
  
Abbott Architect 10 19 10 2 2 6 
Beckman Synchron 11 15 11 8 9 6 
OCD Vitros 5 11 8 2 2 4 
Roche Cobas ElecSys 38 81 11 15 22 5 
Siemens Centaur 8 25 11 3 4 4 
Siemens Vista 4 7 9 3 5 7 
 3 
 4 
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Legend to Figures 
 
Figure 1 Illustration of the match between the median values per 
manufacturer/instrument for FT4 and TSH in the Percentiler application in this study 
(blue lines) and those in the Phase I method comparison study (red lines) [6,7]. 
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Figure 2 Examples of Percentiler graphs. Each colored line represents a single 
instrument in a laboratory; the long broken gray line shows the long-term median of 
the laboratory, while the black short broken line represents the peer group moving 
median. The shaded area between the short broken gray lines is the so-called 
stability zone; violation for longer than one week is considered significant. In (A), we 
show the time course of the TSH moving medians for all instruments used in a 
certain laboratory; for all instruments the analytical variability is low, nicely between 
the stability limits, and the medians are, in addition, concordant with the peer group 
median for nearly a year; in (B) we demonstrate a laboratory with a highly variable 
FT4 performance for all instruments; in (C) we document a laboratory with clear shifts 
in the FT4 moving medians outside the stability limits; in (D) we demonstrate that 
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sometimes a laboratory performs with a substantial difference in the medians of the 
instruments it uses (here for TSH) (is to interpret with caution, though as explained in 
the discussion). 
 
Figure 3 Occurrence of two subgroups in a single TSH peer group. The graph shows 
the time course of the TSH moving medians for all instruments from several 
laboratories in a certain peer group. Each line represents a single instrument; the 
long broken gray line shows the long-term median of the entire peer group. The 
shaded area between the short broken gray lines represents the stability zone of ± 
0.12 mIU/L around the peer group “overall” median. The graphs clearly show the 
occurrence of two subgroups within a single peer group, one having the long-term 
median around 1.4 mIU/L, the other around 1.75 mIU/L. 
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Figure 4 Percentiler graph showing an upwards drift for the moving median of FT4 
for two instruments (A), which is mirrored in the Flagger by a decreasing %-hypo (B) 
and increasing %-hyper value (C). When the moving median decreases again around 
September (A), the %-hypo increases (B) and the %-hyper decreases (C). The long 
broken black line (A) shows the peer group median, while the long broken gray line 
shows the long-term median of the patient medians (A) and flagging rates (B and C). 
The shaded area between the short broken gray lines represents the stability zone, 
which should not be violated longer than one week.  
 
